According to Roche, the diagnostic’s expansion into the ultralow category may allow between 20% to 25% of patients whose breast tumors were previously labeled as HR-positive and HER2-negative to ...

As seen in the DESTINY-Breast06 trial, approximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast cancer patients may be considered HER2-ultralow.1 These patients may now ...

Roche is cutting 345 jobs ... The Basel-based drugs and diagnostic maker last week reported 7% lower sales and a 9% drop in net income during 2023 as it tackled a slump in demand for its COVID-19 ...

Roche has a plan to build out its point-of-care diagnostic catalog, with the goal of delivering more tests to homes, pharmacies, doctor’s offices and elsewhere. The company aims to acquire a ...

Meanwhile, Roche’s greatest strength, according to S&P, is its sheer number of blockbuster products at 15 compared to 14 for J&J, 13 for Novartis and a dozen each for AbbVie and AZ.

"This isn't a partisan issue — investing in diagnostic testing is a no-brainer. It is good for all Americans, it makes our communities healthier and makes our economy healthier," Carson said. The city ...